Lassa fever future or investigational therapies: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Researchers at the [[USAMRIID]] facility, where military biologists study infectious diseases, have a promising vaccine candidate. They have developed a [[Virus#Replication|replication]]-competent [[vaccine]] against Lassa virus based on recombinant vesicular [[stomatitis]] [[Vesicular stomatitis virus|virus]] vectors expressing the Lassa virus [[glycoprotein]]. After a single [[Intramuscular|intramuscular injection]], test primates have survived lethal challenge, while showing no clinical symptoms.<ref>{{cite journal |author=Geisbert TW, Jones S, Fritz EA, ''et al'' |title=Development of a new vaccine for the prevention of Lassa fever |journal=PLoS Med. |volume=2 |issue=6 |pages=e183 |year=2005 |pmid=15971954 |doi=10.1371/journal.pmed.0020183}}</ref> | Researchers at the [[USAMRIID]] facility, where military biologists study infectious diseases, have a promising vaccine candidate. They have developed a [[Virus#Replication|replication]]-competent [[vaccine]] against Lassa virus based on recombinant vesicular [[stomatitis]] [[Vesicular stomatitis virus|virus]] vectors expressing the Lassa virus [[glycoprotein]]. After a single [[Intramuscular|intramuscular injection]], test primates have survived lethal challenge, while showing no clinical symptoms.<ref>{{cite journal |author=Geisbert TW, Jones S, Fritz EA, ''et al'' |title=Development of a new vaccine for the prevention of Lassa fever |journal=PLoS Med. |volume=2 |issue=6 |pages=e183 |year=2005 |pmid=15971954 |doi=10.1371/journal.pmed.0020183}}</ref> | ||
Siga Technologies is developing an [[antiviral drug]] that has been shown effective in treating experimentally infected guinea pigs. In a study conducted at the [[USAMRIID|U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)]], treatment with ST-193 once a day for 14 days resulted in significant reduction in mortality (71% of the animals survived at the low dose), whereas all untreated animals and those treated with [[ribavirin]] died within 20 days of the infection.<ref>{{cite press release | |||
| url = http://www.siga.com/press/051507.html | |||
| title = SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193}}</ref> | |||
==References== | ==References== | ||
Revision as of 21:18, 20 December 2012
|
Lassa fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Lassa fever future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Lassa fever future or investigational therapies |
|
Risk calculators and risk factors for Lassa fever future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Researchers at the USAMRIID facility, where military biologists study infectious diseases, have a promising vaccine candidate. They have developed a replication-competent vaccine against Lassa virus based on recombinant vesicular stomatitis virus vectors expressing the Lassa virus glycoprotein. After a single intramuscular injection, test primates have survived lethal challenge, while showing no clinical symptoms.[1]
Siga Technologies is developing an antiviral drug that has been shown effective in treating experimentally infected guinea pigs. In a study conducted at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), treatment with ST-193 once a day for 14 days resulted in significant reduction in mortality (71% of the animals survived at the low dose), whereas all untreated animals and those treated with ribavirin died within 20 days of the infection.[2]
References
- ↑ Geisbert TW, Jones S, Fritz EA; et al. (2005). "Development of a new vaccine for the prevention of Lassa fever". PLoS Med. 2 (6): e183. doi:10.1371/journal.pmed.0020183. PMID 15971954.
- ↑ "SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193" (Press release).